[go: up one dir, main page]

WO2002063008A3 - Molecules de signalisation intracellulaire - Google Patents

Molecules de signalisation intracellulaire Download PDF

Info

Publication number
WO2002063008A3
WO2002063008A3 PCT/US2002/003966 US0203966W WO02063008A3 WO 2002063008 A3 WO2002063008 A3 WO 2002063008A3 US 0203966 W US0203966 W US 0203966W WO 02063008 A3 WO02063008 A3 WO 02063008A3
Authority
WO
WIPO (PCT)
Prior art keywords
intracellular signaling
signaling molecules
provides
intsig
instsig
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/003966
Other languages
English (en)
Other versions
WO2002063008A2 (fr
Inventor
Li Ding
Bridget A Warren
Vicki S Elliot
Y Tom Tang
Henry Yue
Neil Burford
Sally Lee
Thomas W Richardson
Preeti Lal
Danniel B Nguyen
Junming Yang
April J A Hafalia
Craig H Ison
Rajagopal Gururajan
Mariah R Baughin
Yumei E Wang
Monique G Yao
Kavitha Thangavelu
Anita Swarnakar
Jennifer A Griffin
Ian J Forsythe
Brooke M Emerling
Narinder K Chawla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Genomics Inc filed Critical Incyte Genomics Inc
Priority to JP2002562745A priority Critical patent/JP2004532006A/ja
Priority to EP02713563A priority patent/EP1379654A2/fr
Priority to CA002436470A priority patent/CA2436470A1/fr
Priority to US10/467,434 priority patent/US20040092715A1/en
Publication of WO2002063008A2 publication Critical patent/WO2002063008A2/fr
Publication of WO2002063008A3 publication Critical patent/WO2002063008A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des molécules de signalisation intracellulaire humaines (INTSIG) et des polynucléotides identifiant et codant ces molécules de signalisation intracellulaire. L'invention concerne également des vecteurs d'expression, des cellules hôtes, des anticorps, des agonistes et des antagonistes. L'invention concerne par ailleurs des procédés de diagnostic, de traitement et de prévention de troubles associés à l'expression aberrante de molécules de signalisation intracellulaire.
PCT/US2002/003966 2001-02-08 2002-02-07 Molecules de signalisation intracellulaire Ceased WO2002063008A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2002562745A JP2004532006A (ja) 2001-02-08 2002-02-07 細胞内シグナル伝達分子
EP02713563A EP1379654A2 (fr) 2001-02-08 2002-02-07 Molecules de signalisation intracellulaires
CA002436470A CA2436470A1 (fr) 2001-02-08 2002-02-07 Molecules de signalisation intracellulaire
US10/467,434 US20040092715A1 (en) 2002-02-07 2002-02-07 Intracellular signaling molecules

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US26792501P 2001-02-08 2001-02-08
US60/267,925 2001-02-08
US27443501P 2001-03-09 2001-03-09
US60/274,435 2001-03-09
US27781901P 2001-03-21 2001-03-21
US60/277,819 2001-03-21
US28132601P 2001-04-03 2001-04-03
US60/281,326 2001-04-03
US29119501P 2001-05-15 2001-05-15
US60/291,195 2001-05-15
US29155001P 2001-05-16 2001-05-16
US60/291,550 2001-05-16
US29359101P 2001-05-25 2001-05-25
US60/293,591 2001-05-25
US29534801P 2001-06-01 2001-06-01
US60/295,348 2001-06-01

Publications (2)

Publication Number Publication Date
WO2002063008A2 WO2002063008A2 (fr) 2002-08-15
WO2002063008A3 true WO2002063008A3 (fr) 2003-07-10

Family

ID=27575317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/003966 Ceased WO2002063008A2 (fr) 2001-02-08 2002-02-07 Molecules de signalisation intracellulaire

Country Status (4)

Country Link
EP (1) EP1379654A2 (fr)
JP (1) JP2004532006A (fr)
CA (1) CA2436470A1 (fr)
WO (1) WO2002063008A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12311009B2 (en) 2017-08-16 2025-05-27 Lgv1 S.R.L. Methods for treating huntington's disease using a polynucleotide encoding a VTFT isoform of a BPIFB4 protein

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2749569A1 (fr) 2012-12-28 2014-07-02 Annibale Alessandro Puca Variante de protéine BPIFB4

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083687A2 (fr) * 2000-04-29 2001-11-08 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine pax humaine 23, et polynucleotide codant pour ce polypeptide
WO2001087949A1 (fr) * 2000-05-09 2001-11-22 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine pax humaine 9, et polynucleotide codant pour ce polypeptide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083687A2 (fr) * 2000-04-29 2001-11-08 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine pax humaine 23, et polynucleotide codant pour ce polypeptide
WO2001087949A1 (fr) * 2000-05-09 2001-11-22 Shanghai Biowindow Gene Development Inc. Nouveau polypeptide, proteine pax humaine 9, et polynucleotide codant pour ce polypeptide

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 17 March 2001 (2001-03-17), STRAUSBERG R: "Homo sapiens clone MGC10870", XP002222119, retrieved from EBI Database accession no. BC004290 *
DATABASE EMBL [online] 3 April 1997 (1997-04-03), NCI-CGAP: "Homo sapiens cDNA clone", XP002222118, retrieved from EBI Database accession no. AA280896 *
DATABASE EMBL [online] 9 September 1999 (1999-09-09), NCI-CGAP: "Homo sapiens cDNA clone", XP002222117, retrieved from EBI Database accession no. AI989569 *
DATABASE EMBL [online] Database accession no. AAU12109 *
DATABASE EMBL [online] Database accession no. ABB75879 *
RICHARDS JOANNE S: "New signaling pathways for hormones and cyclic adenosine 3',5'-monophosphate action in endocrine cells.", MOLECULAR ENDOCRINOLOGY, vol. 15, no. 2, February 2001 (2001-02-01), pages 209 - 218, XP002222116, ISSN: 0888-8809 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12311009B2 (en) 2017-08-16 2025-05-27 Lgv1 S.R.L. Methods for treating huntington's disease using a polynucleotide encoding a VTFT isoform of a BPIFB4 protein

Also Published As

Publication number Publication date
CA2436470A1 (fr) 2002-08-15
EP1379654A2 (fr) 2004-01-14
JP2004532006A (ja) 2004-10-21
WO2002063008A2 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
WO2000070049A3 (fr) Molecules de signalisation extracellulaires
WO2002046383A3 (fr) Molecules de modification et de maintenance proteiques
WO2002063005A3 (fr) Molecules associees a des lipides
WO2003031568A3 (fr) Molecules de signalisation intracellulaire
WO2002097060A3 (fr) Proteines associees aux carbohydrates
WO2004053068A3 (fr) Molecules de modification et de maintenance de proteines
WO2003060064A3 (fr) Molecules de signalisation intracellulaire
WO2002026950A3 (fr) Transferases
WO2002034783A3 (fr) Proteines transmembranaires
WO2002101008A3 (fr) Molecules intracellulaires de signalisation
WO2003063688A3 (fr) Molecules de modification et d'entretien de proteines
WO2004009797A3 (fr) Molecules de modification et d'entretien de proteines
WO2002060942A3 (fr) Molecules de modification et de maintenance proteiques
WO2000077040A3 (fr) Molecules de signalisation intracellulaires
WO2003039348A3 (fr) Molecules de signalisation intracellulaire
WO2002066646A3 (fr) Proteines associees a la neurotransmission
WO2003031939A3 (fr) Molecules proteiques de modification et d'entretien
WO2001092527A3 (fr) Regulateurs de l'apoptose
WO2003083084A3 (fr) Molecules de modification et d'entretien de proteines
WO2001094391A3 (fr) Proteines de signalisation intracellulaires
WO2002031152A3 (fr) Molecules de signalisation intracellulaire
WO2003025150A3 (fr) Molecules associees a des lipides
WO2002063008A3 (fr) Molecules de signalisation intracellulaire
WO2004067712A3 (fr) Molecules de signalisation intracellulaire
WO2002094988A3 (fr) Molecules associees a des lipides

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2436470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10467434

Country of ref document: US

Ref document number: 2002562745

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002713563

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002713563

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002713563

Country of ref document: EP